Archive for the ‘bristol-myers_squibb’ tag
Abilify
Alca-Luftal – knot – woman
Click here to see it on AdPharm
AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.
Alca-Luftal – knot – man
Click here to see it on AdPharm
AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.
Plavix – Living Proof
Living proof
ACS – PAD – Stroke – PAD – ACS
4 large trials involving more than 81,000 patients.
Plavix ??? the only prescription antiplatelet with proven efficacy and a well-established safety profile in a broad range of patients.
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix, by Sun Pharmaceuticals under the trade name Clopilet, by Ranbaxy Laboratories under the trade name Ceruvin. It works by irreversibly inhibiting a receptor called P2Y12. Adverse effects include hemorrhage.
Brand name: Plavix
Generic name/category: Clopidogrel, Antiplatelet drugs, ADP receptor inhibitors, Thiophenes, Prodrugs
Company: Sanofi-Aventis and Bristol-Myers Squibb
Country/Market: USA, North America
Indication(s)/use: inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease
Target: Healthcare Professionals (HCP)
Tagline: Living Proof.
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: The Journal of Invasive Cardiology – September 2009
To see all of this brand's ads on AdPharm, click here
0 views
Sep 11, 2009
Visit AdPharm.net for more pharmaceutical ads
Abilify Canada
Voici Abilify, indiqu?© dans le traitement de la schizophr?©nie.
Parce que les sympt??mes n?©gatifs font aussi partie de la route.
Une att?©nuation des sympt??mes positifs et n?©gatifs a ?©t?© d?©montr?©e avec Abilify.
Nouveau Abilify.
Here's Abilify, indicated for the treatment of schizophrenia.
Because negative symptoms are also part of the road.
Mitigation of positive and negative symptoms has been demonstrated with Abilify.
New Abilify.
Aripiprazole (marketed as Abilify, Abilify Discmelt; also known as BMS 337039, OPC-14597, and APZ) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently, it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, and as an adjunct for the treatment of major depressive disorder. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.
Brand name: Abilify
Generic name/category: Aripiprazole, Atypical antipsychotics, Piperazines
Company: Bristol-Myers Squibb (BMS)
Country/Market: Canada, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Le M?©decin du Qu?©bec – September 2009
To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009
Visit AdPharm.net for more pharmaceutical ads
Sustiva – skyline
Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, the United States Department of Health and Human Services Panel on Antiretroviral Guidelines currently recommends the use of efavirenz in combination with lamivudine/zidovudine (Combivir) or tenofovir/emtricitabine (Truvada) as the preferred NNRTI-based regimens in adults and adolescents.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
The usual adult dose is 600 mg once a day. It is usually taken on an empty stomach at bedtime to reduce neurological and psychiatric adverse effects.
Efavirenz was combined with the popular HIV medication Truvada, which consists of tenofovir and emtricitabine, all of which are reverse transcriptase inhibitors. This combination of three medications approved by the U.S. Food and Drug Administration (FDA) in July 2006 under the brand name Atripla, provides HAART in a single tablet taken once a day. It results in a simplified drug regimen for many patients.
Brand name: Sustiva
Generic name/category: Efavirenz, Non-nucleoside reverse transcriptase inhibitors, Alkynes, World Health Organization essential medicines
Company: Bristol-Myers Squibb BMS
Country/Market: USA, North America
Indication(s)/use: HIV combination therapy
Target: Healthcare Professionals (HCP)
Tagline: Thousands of stories
Medium: Web banner
Size/duration: 728X90
Publication/Aired: www.infectiousdiseasenews.com – September 2009
0 views
Sep 03, 2009
Visit AdPharm.net for more pharmaceutical ads
